Ehsan, H.; Robinson, M.; Voorhees, P.M.; Cassetta, K.; Borden, S.; Atrash, S.; Bhutani, M.; Varga, C.; Pineda-Roman, M.; Friend, R.;
et al. Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study). Life 2024, 14, 384.
https://doi.org/10.3390/life14030384
AMA Style
Ehsan H, Robinson M, Voorhees PM, Cassetta K, Borden S, Atrash S, Bhutani M, Varga C, Pineda-Roman M, Friend R,
et al. Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study). Life. 2024; 14(3):384.
https://doi.org/10.3390/life14030384
Chicago/Turabian Style
Ehsan, Hamid, Myra Robinson, Peter M. Voorhees, Kristen Cassetta, Shanice Borden, Shebli Atrash, Manisha Bhutani, Cindy Varga, Mauricio Pineda-Roman, Reed Friend,
and et al. 2024. "Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)" Life 14, no. 3: 384.
https://doi.org/10.3390/life14030384
APA Style
Ehsan, H., Robinson, M., Voorhees, P. M., Cassetta, K., Borden, S., Atrash, S., Bhutani, M., Varga, C., Pineda-Roman, M., Friend, R., & Paul, B. A.
(2024). Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study). Life, 14(3), 384.
https://doi.org/10.3390/life14030384
